Insilico Medicine
3696AI-driven drug-discovery company whose generative models design and prioritise drug candidates, several of which it has advanced into its own clinical trials.
Products
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Pharma.AI Platform
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
-
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.
-
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.
-
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
-
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
-
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
-
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
-
MMAI Gym Platform
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
Closest alternatives 1
Similar products 105
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Total funding
-
Regulatory filing · 18 Dec 2025
Prospectus 'Pre-IPO Investments' table (p.202), 'Total funds raised by our Company' column sums to US$530.3M across 8 rounds (Series A 6.0, B 36.8, C1 68.2, C2 186.8, C+ 15.0, D 60.2, D-2 34.5, E 122.8). Supersedes a clay.com (third-party-database) citation.
- Market cap
-
Third-party database · 24 Sep 2026
HKEX 3696 market cap HKD 33.77B on 2026-09-24, converted at 7.78.
- Employees
-
Regulatory filing · 30 Jun 2026
2026 interim report, p.36: "As of June 30, 2026, the Group had 333 employees and consultants." Supersedes a LinkedIn '10,000+' band (a refused source kind).
- Founded
-
Founded 2014 by Alex Zhavoronkov.
- Revenue (TTM)
-
Regulatory filing · 30 Jun 2026
TTM to 2026-06-30 = FY2025 US$56.2M (annual report) - H1 2025 US$27.5M + H1 2026 US$106.3M (interim report: "revenue increased by US$78.8 million or 287.2% from US$27.5 million for the six months ended June 30, 2025").
Open Insilico Medicine in the directory
Something wrong here? Send a correction — quote this company id: insilico-medicine.